Arcutis Biotherapeutics, Inc. ARQT
Set alert
At close · Oct 30
After hours · Oct 30, 6:21 PM ET
- YTD
- +10.43%
- 1 year
- +28.69%
- Open
- 32.34
- Prev close
- 31.97
- Mkt cap
- 4.03B
- Vol
- 1.88M
- Avg vol
- 2.50M
- EPS
- 0.22
- P/E
- 145.77
- Div yield
- 0.00%
More statistics
- Low
- 31.67
- High
- 32.56
- Forward P/E
- 23.96
- Beta
- 1.58
- Short ratio
- 6.13
- Inst. own
- 108.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 26.53
- 200-d avg
- 25.22
- 1y target
- 39.13
5D chart
Signals (142)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
4 days ago zacks.com
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago globenewswire.com
Arcutis Appoints Rob Scott, MD to Board of Directors
Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.
5 days ago globenewswire.com
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in…
1 week ago globenewswire.com
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.
1 week ago defenseworld.net
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,728 Shares of Company Stock
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) Director Howard Welgus sold 4,728 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at…
-
1 week ago benzinga.com
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
2 weeks ago benzinga.com
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales…
2 weeks ago benzinga.com
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
-
2 weeks ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.
-
3 weeks ago benzinga.com
Arcutis Presents ZORYVE Data At EADV Congress
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and…
3 weeks ago globenewswire.com
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to
3 weeks ago globenewswire.com
Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is…
4 weeks ago defenseworld.net
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat…
1 month ago globenewswire.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in…
1 month ago defenseworld.net
Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) insider Masaru Matsuda sold 3,674 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The stock…
1 month ago zacks.com
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in…
1 month ago seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
1 month ago globenewswire.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in…
2 months ago globenewswire.com
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in…
2 months ago zacks.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
2 months ago zacks.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
2 months ago defenseworld.net
Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT
Bamco Inc. NY acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the second quarter, according to the company in its most recent Form 13F filing with the…
2 months ago zacks.com
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and…
2 months ago defenseworld.net
382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AG
Deutsche Bank AG bought a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
-
2 months ago benzinga.com
Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
Health Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger childrenThe 0.05% formulation was specifically selected for…
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
-
2 months ago benzinga.com
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
-
2 months ago benzinga.com
Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.03 by 266.67 percent. This is a 184.62 percent increase over…
-
3 months ago benzinga.com
FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05%
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1…
-
4 months ago benzinga.com
Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for use…
-
5 months ago benzinga.com
UPDATE: Arcutis Highlights New Expert Guidance For Diagnosing And Managing Genital Psoriasis Across All Age Groups
Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populationsThis is the second published manuscript from the…
-
5 months ago benzinga.com
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
-
5 months ago benzinga.com
Arcutis Biotherapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $105.398M Beat $101.261M Estimate
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of…
-
6 months ago benzinga.com
Arcutis Biotherapeutics Announces Submission Of sNDA To FDA Seeking To Expand Indication For ZORYVE Cream 0.05% To Include Topical Treatment Of Atopic Dermatitis In Infants Down To 3 Months
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitisOnce-daily ZORYVE cream was well…
-
6 months ago benzinga.com
Arcutis Biotherapeutics Announces ZORYVE Cream Receives Strong Recommendation, With High Certainty Of Clinical Evidence, In AAD Clinical Practice Guidelines For Management Of Pediatric Atopic Dermatitis
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4)…
-
7 months ago benzinga.com
Reported Saturday, Arcutis' Phase 2 INTEGUMENT-INFANT Trial Shows Zoryve Cream 0.05% Achieves 49% Clear Or Almost Clear Skin And 58.3% EASI-75 In Infants With Atopic Dermatitis
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms…
-
7 months ago benzinga.com
Arcutis Biotherapeutics To Present New Data From Its Clinical Development Program And Marketed ZORYVE Portfolio
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new…
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
11 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
1 year ago benzinga.com
Earnings Scheduled For October 28, 2025
Earnings Scheduled For October 28, 2025
1 year ago benzinga.com
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your…